Clinical trial design in the era of precision medicine.

Recent rapid biotechnological breakthroughs have led to the identification of complex and unique molecular features that drive malignancies. To overcome cancer complexity, moving from drug-centric to patient-centric individualized combination therapy is critical.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Precision medicine has exploited next-generation sequencing and matched targeted therapy/immunotherapy deployment to successfully transform the outlook for several fatal cancers.
• 2 Tumor and liquid biopsy genomic profiling and transcriptomic, immunomic, and proteomic interrogation can now all be leveraged to optimize therapy.
• 3 Multiple new trial designs, including basket and umbrella trials, master platform trials, and N-of-1 patient-centric studies, are beginning to supplant standard phase I, II, and III protocols, allowing for accelerated drug evaluation and approval and molecular-based individualized treatment.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: